Stanley Laman Group Ltd. Makes New $9.05 Million Investment in Shockwave Medical, Inc. (NASDAQ:SWAV)

Stanley Laman Group Ltd. bought a new stake in Shockwave Medical, Inc. (NASDAQ:SWAV) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 47,471 shares of the company’s stock, valued at approximately $9,046,000. Shockwave Medical accounts for approximately 1.4% of Stanley Laman Group Ltd.’s portfolio, making the stock its 9th biggest position. Stanley Laman Group Ltd. owned approximately 0.13% of Shockwave Medical at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. Motley Fool Asset Management LLC increased its holdings in shares of Shockwave Medical by 577.9% in the 4th quarter. Motley Fool Asset Management LLC now owns 63,807 shares of the company’s stock valued at $12,159,000 after acquiring an additional 54,394 shares during the period. South Dakota Investment Council increased its holdings in shares of Shockwave Medical by 55.8% in the 4th quarter. South Dakota Investment Council now owns 9,524 shares of the company’s stock valued at $1,815,000 after acquiring an additional 3,410 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Shockwave Medical by 0.9% in the 4th quarter. New York State Common Retirement Fund now owns 209,395 shares of the company’s stock valued at $39,902,000 after acquiring an additional 1,945 shares during the period. Jennison Associates LLC grew its position in Shockwave Medical by 13.1% in the 4th quarter. Jennison Associates LLC now owns 100,551 shares of the company’s stock valued at $19,161,000 after buying an additional 11,651 shares during the last quarter. Finally, Cetera Trust Company N.A purchased a new position in Shockwave Medical in the 4th quarter valued at $152,000. 95.35% of the stock is owned by institutional investors and hedge funds.

Shockwave Medical Stock Up 0.0 %

Shares of Shockwave Medical stock traded up $0.12 on Thursday, hitting $328.99. 597,448 shares of the company’s stock traded hands, compared to its average volume of 959,437. The stock has a market cap of $12.30 billion, a P/E ratio of 85.01, a PEG ratio of 2.44 and a beta of 0.92. The company has a quick ratio of 10.73, a current ratio of 11.76 and a debt-to-equity ratio of 1.09. The firm’s 50-day moving average is $293.53 and its 200 day moving average is $232.36. Shockwave Medical, Inc. has a 52-week low of $157.00 and a 52-week high of $331.58.

Shockwave Medical (NASDAQ:SWAV) last posted its quarterly earnings results on Thursday, February 15th. The company reported $1.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.24. Shockwave Medical had a return on equity of 23.97% and a net margin of 20.17%. The business had revenue of $202.98 million for the quarter, compared to analyst estimates of $199.43 million. During the same period in the prior year, the company posted $3.71 EPS. The business’s revenue was up 41.0% compared to the same quarter last year. Equities analysts anticipate that Shockwave Medical, Inc. will post 4.94 earnings per share for the current year.

Insider Activity

In related news, insider Isaac Zacharias sold 4,000 shares of the firm’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $224.69, for a total transaction of $898,760.00. Following the completion of the transaction, the insider now owns 63,920 shares of the company’s stock, valued at $14,362,184.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, insider Isaac Zacharias sold 4,000 shares of the stock in a transaction on Friday, January 26th. The stock was sold at an average price of $224.69, for a total value of $898,760.00. Following the completion of the transaction, the insider now owns 63,920 shares in the company, valued at approximately $14,362,184.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Laura Francis sold 1,500 shares of the stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $300.00, for a total value of $450,000.00. Following the completion of the transaction, the director now owns 3,551 shares of the company’s stock, valued at approximately $1,065,300. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 93,813 shares of company stock valued at $23,762,679. Company insiders own 3.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wolfe Research restated a “peer perform” rating on shares of Shockwave Medical in a research report on Friday, April 5th. Leerink Partnrs downgraded shares of Shockwave Medical from an “outperform” rating to a “market perform” rating in a research note on Friday, April 5th. CL King reissued a “neutral” rating on shares of Shockwave Medical in a research note on Monday, April 8th. Wells Fargo & Company upped their price objective on shares of Shockwave Medical from $200.00 to $210.00 and gave the company an “equal weight” rating in a research note on Friday, February 16th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $335.00 price objective (up previously from $285.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Ten investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Shockwave Medical presently has an average rating of “Hold” and an average target price of $309.11.

Shockwave Medical Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.